Manufacturing updates: Canada gives $62M to Entos, Vetter expands in Germany, EU launches Critical Medicines Act, Noramco invests $25M in NJ, plus deals from WuXi XDC, Emergent BioSolutions & RoslinCT ...

Endpoints Health Tech newsletter wins SABEW award for business journalism, recognized for coverage of healthcare industry issues including weight loss drugs and value-based care.

Now that President-elect Donald Trump has made his choice for FDA commissioner, reactions and analysis are pouring in from biopharma executives and former staffers who know the agency’s inner ...

Plus, news about Oruka Therapeutics, Centessa, Takeda, Innate Pharma and Liquidia: GSK’s mRNA flu vaccine succeeds against both strains in Phase 2: The pharma company ...

The Parker Institute for Cancer Immunotherapy, a research network established by tech entrepreneur Sean Parker, announced a new $125 million investment. The latest investment comes from Parker and ...

Vertex sued the federal government on Monday in an effort to expand its fertility support program to certain patients taking its new gene therapy for sickle cell disease and transfusion ...

To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year ...

Just over three months into his new role as the CEO of Recipharm, Greg Behar is already making sizable changes to the CDMO’s engine. “I've been studying the company deeply ...

Novo Nordisk spelled out how it will try to catch up with the extraordinary demand for its GLP-1 drugs, underscoring its rationale for its in-house API production and strategic fill ...

ARCH Venture Partners plans to raise $3 billion for its 13th fund, per a new SEC filing from this week. The Chicago-based venture capital firm has ...

Gene therapy startup enGene became a public biotech on Wednesday after completing its combination with Forbion European Acquisition, a blank check company formed in 2021. The Montreal and ...

All com­pa­nies with drugs on CMS’ list for the first round of Medicare price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act have agreed to par­tic­i­pate as … ...